5-Fluorouracil

• CAT Number: I003837
• CAS Number: 51-21-8
• Molecular Formula: C4H3FN2O2
• Molecular Weight: 130.1
• Purity: ≥95%
• Target: HIV Integrase
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: 2-8°C
• IUPAC Name: 5-fluoro-1H-pyrimidine-2,4-dione
• InChI: InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
• InChIKey: GHASVSINZRGABV-UHFFFAOYSA-N
• SMILES: C1=C(C(=O)NC(=O)N1)F

5-Fluorouracil (Cat No.:I003837) is a highly effective antitumor agent used in cancer treatment. It exerts its therapeutic effects by interfering with the synthesis of pyrimidines, which are essential building blocks of DNA and RNA. Specifically, 5-FU inhibits the activity of the enzyme thymidylate synthetase, which is responsible for producing thymidine monophosphate (dTMP), a precursor of DNA. By inhibiting thymidylate synthetase, 5-FU reduces the levels of dTMP, leading to a depletion of intracellular deoxythymidine triphosphate (dTTP) pools. This disruption in nucleotide synthesis ultimately hampers cancer cell proliferation and contributes to the antitumor effects of 5-FU.

Reference

1:Establishment of 5-Fluorouracil-resistant canine mammary tumor cell line. Zhou B, Zhang D, Pei SM, Zhang H, Du HC, Jin YP, Lin DG.Pol J Vet Sci. 2017 Mar 28;20(1):103-110. doi: 10.1515/pjvs-2017-0014. PMID: 28525328 2:Coronary vasospasm associated with 5-fluorouracil chemotherapy: Cardiac toxicity or cardiac hypersensitivity? Kounis NG, Koniari I, Patsouras N, Koutsogiannis N, Velissaris D, Soufras G, Hahalis G.Am J Emerg Med. 2017 May 12. pii: S0735-6757(17)30369-8. doi: 10.1016/j.ajem.2017.05.005. [Epub ahead of print] No abstract available. PMID: 28521972 3:MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase. Xu W, Jiang H, Zhang F, Gao J, Hou J.Oncol Lett. 2017 May;13(5):3387-3394. doi: 10.3892/ol.2017.5895. Epub 2017 Mar 23. PMID: 28521444 4:Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis. Li Z, Zhang P, Ma Q, Wang D, Zhou T.Mol Clin Oncol. 2017 May;6(5):743-747. doi: 10.3892/mco.2017.1222. Epub 2017 Apr 10. PMID: 28515926 5:Translational reprogramming of colorectal cancer cells induced by 5-Fluorouracil through a miRNA-dependent mechanism. Zeina BI, Gabriel T, Anne V, Florian L, Micaela PE, Nathalie P, Françoise M, Julie P, Alexandre D, Jean-Christophe S, Mertani HC, Julien T, Didier A, Frédéric C, Nicole DV, Martin D, Virginie M, Jean-Jacques D.Oncotarget. 2017 May 3. doi: 10.18632/oncotarget.17597. [Epub ahead of print] PMID: 28515355 Free Article6:miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma. Jiao D, Yan Y, Shui S, Wu G, Ren J, Wang Y, Han X.Oncotarget. 2017 May 2. doi: 10.18632/oncotarget.17577. [Epub ahead of print] PMID: 28514741 Free Article7:Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil. Przybyła T, Sakowicz-Burkiewicz M, Maciejewska I, Bielarczyk H, Pawełczyk T.Acta Biochim Pol. 2017 May 17. doi: 10.18388/abp.2016_1421. [Epub ahead of print] PMID: 28510612 Free Article8:Effect of mTHPC-mediated photodynamic therapy on 5-fluorouracil resistant human colorectal cancer cells. Kukcinaviciute E, Sasnauskiene A, Dabkeviciene D, Kirveliene V, Jonusiene V.Photochem Photobiol Sci. 2017 May 16. doi: 10.1039/c7pp00014f. [Epub ahead of print] PMID: 28509917 9:Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma. Chavani O, Jensen BP, Strother RM, Florkowski CM, George PM.J Pharm Biomed Anal. 2017 May 6;142:125-135. doi: 10.1016/j.jpba.2017.04.055. [Epub ahead of print] PMID: 28501750 10:A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Inhestern J, Schmalenberg H, Dietz A, Rotter N, Maschmeyer G, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Sudhoff H, Wittekindt C, Guntinas-Lichius O.Ann Oncol. 2017 May 11. doi: 10.1093/annonc/mdx202. [Epub ahead of print] PMID: 28498880